aTyr Pharma restructures: 60% workforce cut, CFO change, $58.9M cash, Phase 3 protocol pending FDA

aTYR PHARMA INC

Workforce reduction of ~60% and annualized opex savings of ~$13M starting Q4 2026.
CFO Jill Broadfoot steps down Sept 30, 2026; Brandon Yaras becomes CFO Oct 1, 2026.
Q2 2026 cash $58.9M; runway into late 2028; R&D $6.7M, G&A $4.1M.
Phase 3 protocol for efzofitimod in pulmonary sarcoidosis submitted to FDA June 2026; feedback expected by end of August 2026.
Phase 2 EFZO-CONNECT in SSc-ILD enrollment completed; topline results expected Q1 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.